Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104477 | 0.95 | PIK3CD (0.61) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL9812335 | 0.92 | PIK3CD (0.50) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL628723 | 0.92 | PIK3CD (0.50) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL12197894 | 0.89 | PIK3CD (0.58) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL5502986 | 0.88 | PIK3CD (0.58) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL4327116 | 0.88 | PIK3CD (0.58) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL7591221 | 0.86 | PIK3CD (0.45) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL175247 | 0.85 | PIK3CD (0.47) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL28499079 | 0.85 | PIK3CD (0.47) | PIK3CDLMNAKMT2AMEN1PKM | |
| SCHEMBL119861 | 0.85 | PIK3CD (0.47) | PIK3CDLMNAKMT2AMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-3901147-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020151589-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2020-07-30 | — | — | WO | disclosed |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-03-10 | — | — | US | disclosed |
| EP-1904600-A2 | COMPOSITIONS COMPRISING 3,3,4,4,5,5,6,6,6-NONAFLUORO-1-HEXENE | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1751247-A2 | 1,1,1,2,2,4,5,5,5-NONAFLUORO-4-(TRIFLUOROMETHYL)-3-PENTANONE COMPOSITIONS COMPRISING A HYDROFLUOROCARBON AND USES THEREOF | E.I.Du pont de nemours and company (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1751246-A2 | 1,1,1,2,2,4,5,5,5-NONAFLUORO-4-(TRIFLUOROMETHYL)-3-PENTANONE REFRIGERANT COMPOSITIONS COMPRISING A HYDROCARBON AND USES THEREOF | E.I.Du pont de nemours and company (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2006130406-A2 | COMPOSITIONS COMPRISING 3,3,4,4,5,5,6,6,6-NONAFLUORO-1-HEXENE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-12-07 | — | — | WO | disclosed |
| EP-1720953-A2 | HALOKETONE REFRIGERANT COMPOSITIONS AND USES THEREOF | E.I. DUPONT DE NEMOURS AND COMPANY, Legal Patent Records Center (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005119143-A2 | 1,1,1,2,2,4,5,5,5-NONAFLUORO-4-(TRIFLUOROMETHYL)-3-PENTANONE COMPOSITIONS COMPRISING A HYDROFLUOROCARBON AND USES THEREOF | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005119144-A2 | 1,1,1,2,2,4,5,5,5-NONAFLUORO-4-(TRIFLUOROMETHYL)-3-PENTANONE REFRIGERANT COMPOSITIONS COMPRISING A HYDROCARBON AND USES THEREOF | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005094395-A2 | HALOKETONE REFRIGERANT COMPOSITIONS AND USES THEREOF | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | RIPK1, RIPK3, RIPK4 | PIK3CD 1587/4885LMNA 2659/4885KMT2A 2048/4885 |
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | PIK3CD 4233/4885LMNA 2671/4885KMT2A 624/4885 |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | PIK3CD 4233/4885LMNA 2671/4885KMT2A 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.